Hostname: page-component-7c8c6479df-p566r Total loading time: 0 Render date: 2024-03-28T17:14:17.354Z Has data issue: false hasContentIssue false

Introduction-Neuroprotection: A Therapeutic Strategy to Prevent Deterioration Associated with Schizophrenia

Published online by Cambridge University Press:  07 November 2014

Jeffrey A. Lieberman*
Affiliation:
Dr. Lieberman is Lawrence C. Kolb Chairman of Psychiatry at, Columbia University College of Physicians and Surgeons, and director of the New York State Psychiatric Institute in New York City

Abstract

Schizophrenia is a neurodevelopmental disorder associated with persistent symptomatology, severe functional disability, and residual morbidity characteristic of neurodegenerative brain diseases. The illness begins with genetic susceptibility and generally expresses itself after puberty through subtle changes that begin during the prodromal stage. Symptoms get progressively worse and tend to become more resistant to treatment with each relapse. Evidence for a neuroprotective effect of some forms of early treatment is beginning to emerge. While the underlying mechanisms remain uncertain, atypical antipsychotics may counteract some of the progressive deteriorative effects by enhancing synaptic plasticity and cellular resilience. However, identifying and treating patients in the earliest disease states presents methodological challenges as there is no consensus on the best methods of intervention and differences in at-risk children are not readily detectable or substantial enough to predict which ones will develop schizophrenia.

In this expert roundtable supplement, Jeffrey A. Lieberman, MD, reviews the historical context of progressive deterioration in schizophrenia. Next, Diana O. Perkins, MD, MPH, reviews some of the challenges to early identification of illness as well as the impact of early versus delayed treatment. Finally, L. Fredrik Jarskog, MD, focuses on the neurobiology of functional progression in schizophrenia as well as pharmacology and the potential for neuroprotection.

Type
Research Article
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kraepelin, E. Dementia Praecox. Barclay, E, Barclay, S, trans. New York, NY: Churchill Livingstone Inc; 1919/1971.Google Scholar